1643

Modern Chinese Medicine GroupSEHK:1643 Stock Report

Market Cap

HK$450.0m

7D

-9.6%

1Y

n/a

Updated

19 Sep, 2021

Data

Company Financials
1643 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance4/6
Financial Health6/6
Dividends0/6

1643 Overview

Modern Chinese Medicine Group Co., Ltd., an investment holding company, produces and sells Chinese medicines in the People's Republic of China.

Share Price & News

How has Modern Chinese Medicine Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1643 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 1643's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

-9.6%

1643

-4.8%

HK Pharmaceuticals

-4.6%

HK Market


1 Year Return

n/a

1643

-14.5%

HK Pharmaceuticals

5.2%

HK Market

Return vs Industry: Insufficient data to determine how 1643 performed against the Hong Kong Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how 1643 performed against the Hong Kong Market.


Shareholder returns

1643IndustryMarket
7 Day-9.6%-4.8%-4.6%
30 Day-2.6%-3.6%2.9%
90 Day-12.8%-23.0%-10.3%
1 Yearn/a-13.4%-14.5%9.0%5.2%
3 Yearn/a-10.1%-15.7%10.5%-2.1%
5 Yearn/a48.7%33.6%29.9%6.5%

Long-Term Price Volatility Vs. Market

How volatile is Modern Chinese Medicine Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Modern Chinese Medicine Group Fundamentals Summary

How do Modern Chinese Medicine Group's earnings and revenue compare to its market cap?
1643 fundamental statistics
Market CapCN¥373.92m
Earnings (TTM)CN¥67.78m
Revenue (TTM)CN¥322.53m

5.5x

P/E Ratio

1.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
1643 income statement (TTM)
RevenueCN¥322.53m
Cost of RevenueCN¥178.28m
Gross ProfitCN¥144.25m
ExpensesCN¥76.47m
EarningsCN¥67.78m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.13
Gross Margin44.72%
Net Profit Margin21.01%
Debt/Equity Ratio0%

How did 1643 perform over the long term?

See historical performance and comparison

Valuation

Is Modern Chinese Medicine Group undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 1643 (HK$0.75) is trading below our estimate of fair value (HK$1.72)

Significantly Below Fair Value: 1643 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 1643 is good value based on its PE Ratio (5.5x) compared to the Hong Kong Pharmaceuticals industry average (9.8x).

PE vs Market: 1643 is good value based on its PE Ratio (5.5x) compared to the Hong Kong market (10x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1643's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1643 is overvalued based on its PB Ratio (1.2x) compared to the HK Pharmaceuticals industry average (1.1x).


Future Growth

How is Modern Chinese Medicine Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

13.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Modern Chinese Medicine Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Modern Chinese Medicine Group performed over the past 5 years?

20.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1643 has a high level of non-cash earnings.

Growing Profit Margin: 1643's current net profit margins (21%) are lower than last year (21.7%).


Past Earnings Growth Analysis

Earnings Trend: 1643's earnings have grown significantly by 20.5% per year over the past 5 years.

Accelerating Growth: 1643's earnings growth over the past year (25.3%) exceeds its 5-year average (20.5% per year).

Earnings vs Industry: 1643 earnings growth over the past year (25.3%) exceeded the Pharmaceuticals industry 23.8%.


Return on Equity

High ROE: 1643's Return on Equity (22.6%) is considered high.


Financial Health

How is Modern Chinese Medicine Group's financial position?


Financial Position Analysis

Short Term Liabilities: 1643's short term assets (CN¥287.2M) exceed its short term liabilities (CN¥47.3M).

Long Term Liabilities: 1643's short term assets (CN¥287.2M) exceed its long term liabilities (CN¥29.0K).


Debt to Equity History and Analysis

Debt Level: 1643 is debt free.

Reducing Debt: 1643 had no debt 5 years ago.

Debt Coverage: 1643 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 1643 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Modern Chinese Medicine Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 1643's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 1643's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1643's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1643's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1643's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Modern Chinese Medicine Group has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: 1643 only recently listed within the past 12 months.


Top Shareholders

Company Information

Modern Chinese Medicine Group Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Modern Chinese Medicine Group Co., Ltd.
  • Ticker: 1643
  • Exchange: SEHK
  • Founded: 1986
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$450.000m
  • Shares outstanding: 600.00m
  • Website: https://www.cdysjdyy.com

Number of Employees


Location

  • Modern Chinese Medicine Group Co., Ltd.
  • No. 88 Jinwei Road
  • Chengde
  • Hebei Province
  • 67000
  • China

Listings


Biography

Modern Chinese Medicine Group Co., Ltd., an investment holding company, produces and sells Chinese medicines in the People's Republic of China. It is also involved in the production and wholesale of Chines...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/19 10:06
End of Day Share Price2021/09/17 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.